Literature DB >> 9124619

Double-blind randomized placebo-controlled trial of the use of granulocyte-macrophage colony-stimulating factor in chronic leg ulcers.

R Marques da Costa1, F M Jesus, C Aniceto, M Mendes.   

Abstract

BACKGROUND: Following encouraging reports on the use of granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat wounds in animals and in man, we conducted a study to test the usefulness of this drug in patients with chronic leg ulcers.
METHODS: Patients received a single perilesional injection of GM-CSF, the effect of which was observed weekly and compared with that of a placebo injection in a control group.
RESULTS: Treated patients fared much better than controls, prompting an early termination of the study: of 16 GM-CSF treated patients, 3 (19%) had their ulcers healed by week 1; 8 (50%) were healed by week 8; only 1 of 9 controls had the ulcer healed by week 1 (11%), and that was the only ulcer of the group that healed at all. We observed no significant side effects or changes in the hematological and biochemical parameters studied.
CONCLUSION: GM-CSF seems a very useful drug for the healing of leg ulcers.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9124619     DOI: 10.1016/s0002-9610(97)89589-x

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  10 in total

1.  The integrin αv-TGFβ signaling axis is necessary for epidermal proliferation during cutaneous wound healing.

Authors:  Elizabeth K Duperret; Christopher A Natale; Christine Monteleon; Ankit Dahal; Todd W Ridky
Journal:  Cell Cycle       Date:  2016-06-13       Impact factor: 4.534

2.  Human pilot studies reveal the potential of a vitronectin: growth factor complex as a treatment for chronic wounds.

Authors:  Zee Upton; Hilary J Wallace; Gary K Shooter; Derek R van Lonkhuyzen; Sim Yeoh-Ellerton; Erin A Rayment; Jacqui M Fleming; Daniel Broszczak; Douglas Queen; R Gary Sibbald; David I Leavesley; Michael C Stacey
Journal:  Int Wound J       Date:  2011-10       Impact factor: 3.315

Review 3.  Advances in the management of leg ulcers--the potential role of growth factors.

Authors:  Muhammad N Khan; Christopher G Davies
Journal:  Int Wound J       Date:  2006-06       Impact factor: 3.315

4.  Advancements in the Delivery of Growth Factors and Cytokines for the Treatment of Cutaneous Wound Indications.

Authors:  Caitlin Berry-Kilgour; Jaydee Cabral; Lyn Wise
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-11-25       Impact factor: 4.730

Review 5.  Clinical application of growth factors and cytokines in wound healing.

Authors:  Stephan Barrientos; Harold Brem; Olivera Stojadinovic; Marjana Tomic-Canic
Journal:  Wound Repair Regen       Date:  2014 Sep-Oct       Impact factor: 3.617

6.  Combined Topical Growth Factor and Protease Inhibitor in Chronic Wound Healing: Protocol for a Randomized Controlled Proof-of-Concept Study.

Authors:  Michael Stacey
Journal:  JMIR Res Protoc       Date:  2018-04-27

Review 7.  Vasculogenic cytokines in wound healing.

Authors:  Victor W Wong; Jeffrey D Crawford
Journal:  Biomed Res Int       Date:  2013-02-28       Impact factor: 3.411

8.  Dressings and topical agents for arterial leg ulcers.

Authors:  Cathryn Broderick; Fania Pagnamenta; Rachel Forster
Journal:  Cochrane Database Syst Rev       Date:  2020-01-20

9.  Summary of recommendations for leg ulcers.

Authors:  Sunil Dogra; Rishu Sarangal
Journal:  Indian Dermatol Online J       Date:  2014-07

Review 10.  Mesenchymal Stem Cell Secretome as an Emerging Cell-Free Alternative for Improving Wound Repair.

Authors:  Parinaz Ahangar; Stuart J Mills; Allison J Cowin
Journal:  Int J Mol Sci       Date:  2020-09-24       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.